GLP-1 Side Effects Tracker
Correlate nausea, constipation, acid reflux, and sulfur burps with your weekly injection timing. Discover dietary fat triggers, model peak-concentration windows, and access evidence-based recovery protocols.
GLPme is a clinical side-effect and symptom tracking app for GLP-1 patients designed to correlate gastrointestinal symptoms with injection timing and meal choices. Rather than guessing why sulfur burps, nausea, or constipation occur, GLPme maps symptoms against your medication's active plasma curve, identifies high-fat food triggers, and provides evidence-based recovery protocols on iOS.
Key takeaways
- Correlates side effects with peak plasma levels ($T_{\max}$ 24–48 hours post-injection).
- Identifies dietary fat triggers: delayed gastric emptying slows fat digestion, inducing nausea and acid reflux.
- Step-by-step GI rescue protocols: osmotic laxative ladders, electrolyte replenishment, and sulfur gas relief.
- Injection site symptom correlation: reveals if switching to thigh injections reduces nausea severity.
- 100% private, on-device logging with zero health data tracking or advertising.
Why tracking symptoms by injection day matters
Gastrointestinal side effects on GLP-1 and dual GIP/GLP-1 medications are not random — they follow predictable pharmacokinetic curves. When patients report "constant nausea," careful logging almost always reveals that symptoms spike precisely 24 to 48 hours after injection (when blood levels peak) or after consuming meals containing more than 15 grams of dietary fat.
GLPme allows you to log symptoms in two taps: record symptom intensity (mild, moderate, severe), timestamp the entry, and view it overlaid against your rolling medication level. This gives your prescriber the exact clinical data needed to adjust titration pacing or prescribe antiemetics.
The $T_{\max}$ peak nausea window
Subcutaneously injected semaglutide and tirzepatide require 24 to 48 hours to be fully absorbed from adipose tissue into systemic circulation ($T_{\max}$). During this peak window, delayed gastric emptying is at its maximum intensity. Food eaten during this window takes significantly longer to leave the stomach. GLPme alerts you when entering your personal $T_{\max}$ window so you can proactively eat smaller, low-fat meals and avoid sulfur gas formation.
Managing the Big Three: Nausea, constipation, and sulfur burps
GLPme incorporates evidence-based clinical protocols for the most common GLP-1 side effects:
- Nausea: Shift injection site from abdomen to the outer thigh (pharmacokinetically proven to reduce peak $C_{\max}$ spikes), sip ice water 30 minutes away from meals, and eat 15g of bland lean protein.
- Constipation: Avoid bulk-forming psyllium husk (Metamucil), which can cause fecal impaction in a slowed gut. Use osmotic agents (polyethylene glycol / MiraLAX or magnesium citrate) paired with 2.5L of water and electrolytes.
- Sulfur Burps: Triggered when dietary proteins and fats ferment in a stalled stomach. Take digestive enzymes or bismuth subsalicylate (Pepto-Bismol), and avoid carbonated beverages and heavy cruciferous vegetables during peak days.
Read our full medical field guide on GLP-1 constipation relief.
Correlating side effects with dietary fat intake
Dietary fat is the most potent inhibitor of gastric motility. Eating a high-fat restaurant meal (e.g. fried foods, heavy cream dressings, cheesy casseroles) on Day 2 post-shot will reliably induce hours of severe nausea and reflux. GLPme's food scanner checks meals for protein-to-fat ratios and gastric comfort scores, protecting your stomach before you take your first bite.
Red flag symptoms that require immediate medical attention
While mild nausea and delayed bowel movements are expected, certain symptoms indicate serious adverse complications:
Sources
Every figure on this page traces to one of these. Regulatory documents and peer-reviewed primary research only — see our editorial policy for what we accept as a source.
- Gorgojo-Martínez JJ et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med, 2023. View source
- American College of Gastroenterology (ACG): Clinical Guideline on the Management of Benign Anorectal Disorders and Chronic Constipation. Am J Gastroenterol, 2023. View source
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. View source
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022. View source
- GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source
Track Your GLP-1 Symptoms with GLPme
Identify food triggers, correlate symptoms with peak plasma levels, and take control of your comfort on iPhone.
